BRAF突变胶质瘤的伴随基因改变与组织学诊断相关
研究对372例胶质瘤行315个癌症相关基因测序,17例(4.6%)存在BRAF突变,其中53%伴p.V600E以外的BRAF改变。胶质母细胞瘤常见TP53、CDKN2A/B缺失、TERT启动子和PTEN改变,E-GBM与PXA以CDKN2A/B缺失伴BRAF p.V600E且无TERTp、TP53、PTEN突变为特征。
要点
- BRAF突变胶质瘤中53%存在p.V600E以外的BRAF改变,应关注伴随分子事件。
- 胶质母细胞瘤常伴CDKN2A/B缺失、TERT启动子及TP53、PTEN改变。
- E-GBM与PXA呈CDKN2A/B缺失伴BRAF p.V600E,且无TERTp、TP53、PTEN突变。
核心结论
- 了解BRAF突变胶质瘤的伴随改变有助于诊断并识别可能从靶向治疗获益的患者。
- 文中报告两例BRAF通路抑制剂治疗后肿瘤有反应的患者。
研究设计与样本
- 单中心2010至2017年372例胶质瘤的315个癌症相关基因二代测序分析。
- 并复习cBioPortal中具突变与拷贝数信息的IDH野生型胶质瘤。
- 共17例(4.6%)检出BRAF突变。
主要发现
- 肿瘤类型包括8例胶质母细胞瘤、2例上皮样胶质母细胞瘤、2例多形性黄色星形细胞瘤等。
- 53%病例存在p.V600E以外的BRAF改变,52.9%肿瘤位于颞叶。
- 胶质母细胞瘤伴TP53突变3/8、CDKN2A/B缺失6/8、TERT启动子改变6/8、PTEN改变5/8。
- E-GBM与PXA均见CDKN2A/B缺失和BRAF p.V600E,无TERTp、TP53、PTEN突变。
- cBioPortal中BRAF突变浸润性胶质瘤呈相似表现。
临床怎么用
- 对BRAF突变胶质瘤应结合伴随分子改变辅助组织学诊断与分型。
- 识别BRAF突变及通路改变可能为靶向治疗选择提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Recently, the term "Diffuse glioma, BRAF V600E-mutant" has been recommended for IDH-wildtype gliomas with BRAF p.V600E mutation and without CDKN2A/B deletion. However, additional alterations in gliomas that coexist with BRAF-mutations are poorly defined. METHODS: We analyzed next-generation sequencing results in 315 cancer-associated genes for 372 gliomas from our institution (2010 to 2017). In addition, we reviewed IDH-WT gliomas with mutation and copy-number alterations available in cBioPortal, to further characterize BRAF-mutant gliomas. RESULTS: Seventeen (4.6%) showed BRAF mutations. Tumor types included 8 glioblastomas, 2 epithelioid glioblastomas (E-GBM), 2 pleomorphic xanthoastrocytomas (PXA), 1 anaplastic oligodendroglioma, 1 diffuse astrocytoma, and 3 pilocytic astrocytomas. Fifty-three percent (53%) of cases exhibited BRAF-alterations other than p.V600E. The majority of the tumors were localized in the temporal lobe (52.9%). In addition to BRAF mutations, glioblastomas showed concomitant mutations in TP53 (3/8), CDKN2A/B-loss (6/8), TERT-promoter (6/8), and/or PTEN (5/8). Both E-GBMs and PXAs showed CDKN2A/B-loss and BRAF p.V600E with absence of TERTp, TP53, and PTEN mutations. Similar findings were observed in BRAF-mutant infiltrating gliomas from cBioPortal. CONCLUSIONS: Knowledge of additional alterations that co-occur with BRAF-mutations in gliomas may improve diagnosis and help identify patients that could benefit from targeted therapies. Furthermore, we provide examples of two patients whose tumors responded to BRAF pathway inhibitors, arguing in favor of these therapies in patients with BRAF-mutant gliomas.
引用
- Dono A, Vu J, Anapolsky M, et al. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. J Neurooncol. 2020. PMID: 33009979. doi:10.1007/s11060-020-03634-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。